Navigation Links
2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer

DÜSSELDORF, Germany, February 4 /PRNewswire-FirstCall/ --

- Sales up by 48% at EUR958 Million - EBITDA Margin Reaches High Level of 19%

- Another Acquisition in the Target Segment of Pharmaceutical Plastics in South America: Brazilian Market Leader for Pharma Plastic Taken Over

According to provisional figures, Gerresheimer AG has just completed another record year. In 2007 the company achieved sales of EUR957.7m, up by 48.1%; the adjusted Group EBITDA margin reached 19%. "This gratifying development completely and fully confirms our strategy," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG: "With the help of acquisitions we have successfully expanded our global presence and set the course for further growth."

Rapid expansion of operations in the South American pharma and life science market

Shortly after taking over EDP S.A. with production in Spain and South America, this international company based in Dusseldorf, Germany, now announces the acquisition of ALLPLAS Embalagens Ltda. (Sao Paulo), which is the market leader for pharmaceutical plastic packaging in Brazil. This marks the successful completion of another important step in the global expansion of the Gerresheimer Group.

For Gerresheimer's Plastic Systems Division, finalisation of the latest contract puts the cap on a dramatic move into South America. It was only at the end of December last year that Gerresheimer, as reported, acquired EDP, the Spanish market leader for pharmaceutical PET bottles, thereby also establishing a foothold in South America for the first time. With Allplas, which operates two production plants in Sao Paulo, Gerresheimer now already has three strategically important bases in the region.

The Brazilian company is a well-established supplier to the pharmaceutical industry, with innovative products and a reputation for high quality. Allplas manufactures high-calibre vials and application and closure systems for liquid formulations and solid dosages (for example eye drops and tablets), which ideally complement - and can be combined with - Gerresheimer's product range. The Group's existing product portfolio in the field of plastic packaging, which has so far been marketed primarily in Europe, will as a result increasingly find its way into the South American pharmaceutical markets.

Allplas currently achieves annual sales equivalent to around EUR16m. The EBITDA margin is 16%, which will be continuously improved in the years ahead. Integration in the Gerresheimer Group is to be completed by mid-2008. Like EDP, Allplas will become part of Gerresheimer Plastic Packaging, which specialises in pharmaceutical primary packaging and application systems under leading trade­marks such as Duma(R), Dudek(TM) and EDP(TM). Together with the two acquisitions, Gerresheimer's plastic operations achieve a total annual sales volume of around EUR350m, of which around EUR100m is attributable to the plastic packaging segment.

About Gerresheimer

Including the two acquisitions, Gerresheimer employs more than 10,800 people in forty locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharmaceutical vials made of glass and plastic to complex drug-delivery systems for the pharma and life-science industry. These include sterile syringes, inhalers and other system solutions for secure dosage and application of medications. The Group enjoys a leading position in a market which is characterised by high technical and regulatory barriers. Gerresheimer's products are subject to extremely rigorous quality requirements stipulated by the international pharmaceutical supervision authorities.

Press Dates

Annual Press Conference February 26 2008

Annual General Meeting April 17, 2008


Burkhard Lingenberg

Director Corporate PR & Marketing

Telephone +49-211-6181-250

Telefax +49-211-6181-241


SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
2. Signalife Receives Another $3.3 Million Sales Orders
3. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
4. CryoLife Announces Record Preservation Services and Product Revenues for 2007
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
9. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
10. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):